NWMP
VKTX icon

Noble Wealth Management PBC’s Viking Therapeutics VKTX Stock Holding History

Noble Wealth Management PBC’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.7K Hold
274
– – ﹤0.01% 464
2026
Q1 		$8.92K Buy
+274
New +$8.81K ﹤0.01% 464

Other funds holding VKTX

WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
CIA
Concurrent Investment Advisors Tampa, Florida $11.8B AUM 31.86% 1-Year Est. Return
RA
RFG Advisory Birmingham, Alabama $6.4B AUM 19.93% 1-Year Est. Return
IFWM
Institute for Wealth Management Denver, Colorado $1.13B AUM 39.73% 1-Year Est. Return
LA
LBP AM Paris, France $10B AUM 43.88% 1-Year Est. Return
ETC
Exchange Traded Concepts Oklahoma City, Oklahoma $21.9B AUM 68.6% 1-Year Est. Return
YIH
Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return
LAM
Lewis Asset Management Lafayette, California $285M AUM 32.52% 1-Year Est. Return
MASM
MH & Associates Securities Management Carlsbad, California $112M AUM
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Noble Wealth Management PBC's VKTX Position: Q2 2026 in Review

Noble Wealth Management PBC held its Viking Therapeutics (VKTX) position steady in Q2 2026 at 274 shares worth $10.7K. The position accounts for ﹤0.01% of the portfolio, ranked #464.

Noble Wealth Management PBC first reported a position in VKTX in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Noble Wealth Management PBC held 274 shares of Viking Therapeutics worth $10.7K as of Q2 2026.
  • Noble Wealth Management PBC left its Viking Therapeutics share count unchanged in Q2 2026.
  • Viking Therapeutics made up ﹤0.01% of Noble Wealth Management PBC's portfolio in Q2 2026, its #464 holding.
  • Noble Wealth Management PBC first reported a position in Viking Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Noble Wealth Management PBC's 13F filing for Q2 2026, filed 1 Jul 2026.